OSE IMMUNO (OSE.PA) Stock Fundamental Analysis
EPA:OSE - Euronext Paris - Matif - FR0012127173 - Common Stock - Currency: EUR
Overall OSE gets a fundamental rating of 5 out of 10. We evaluated OSE against 71 industry peers in the Biotechnology industry. OSE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. OSE has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year OSE was profitable.
OSE had a positive operating cash flow in the past year.
In the past 5 years OSE reported 4 times negative net income.
In the past 5 years OSE reported 4 times negative operating cash flow.
1.2 Ratios
OSE's Return On Assets of 30.21% is amongst the best of the industry. OSE outperforms 98.59% of its industry peers.
OSE has a better Return On Equity (58.68%) than 95.77% of its industry peers.
OSE has a better Return On Invested Capital (30.99%) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.21% | ||
| ROE | 58.68% | ||
| ROIC | 30.99% |
ROA(3y)-5.74%
ROA(5y)-10.16%
ROE(3y)-31.96%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OSE has a Profit Margin of 44.88%. This is amongst the best in the industry. OSE outperforms 97.18% of its industry peers.
OSE has a Operating Margin of 52.42%. This is amongst the best in the industry. OSE outperforms 98.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.42% | ||
| PM (TTM) | 44.88% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OSE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, OSE has about the same amount of shares outstanding.
Compared to 5 years ago, OSE has more shares outstanding
OSE has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.42 indicates that OSE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.42, OSE belongs to the top of the industry, outperforming 87.32% of the companies in the same industry.
OSE has a debt to FCF ratio of 0.95. This is a very positive value and a sign of high solvency as it would only need 0.95 years to pay back of all of its debts.
OSE's Debt to FCF ratio of 0.95 is amongst the best of the industry. OSE outperforms 97.18% of its industry peers.
A Debt/Equity ratio of 0.60 indicates that OSE is somewhat dependend on debt financing.
The Debt to Equity ratio of OSE (0.60) is comparable to the rest of the industry.
Although OSE does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 0.95 | ||
| Altman-Z | 3.42 |
ROIC/WACC4.16
WACC7.45%
2.3 Liquidity
OSE has a Current Ratio of 3.46. This indicates that OSE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of OSE (3.46) is better than 69.01% of its industry peers.
A Quick Ratio of 3.46 indicates that OSE has no problem at all paying its short term obligations.
OSE has a Quick ratio of 3.46. This is in the better half of the industry: OSE outperforms 71.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 225.86% over the past year.
The Revenue has grown by 3646.52% in the past year. This is a very strong growth!
Measured over the past years, OSE shows a very strong growth in Revenue. The Revenue has been growing by 26.31% on average per year.
EPS 1Y (TTM)225.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%372.26%
Revenue 1Y (TTM)3646.52%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%9501.27%
3.2 Future
OSE is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -57.77% yearly.
OSE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -28.54% yearly.
EPS Next Y-82.85%
EPS Next 2Y-63.7%
EPS Next 3Y-57.77%
EPS Next 5YN/A
Revenue Next Year-47.32%
Revenue Next 2Y-20.24%
Revenue Next 3Y-28.54%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 4.06, which indicates a rather cheap valuation of OSE.
Based on the Price/Earnings ratio, OSE is valued cheaply inside the industry as 97.18% of the companies are valued more expensively.
OSE's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.21.
With a Price/Forward Earnings ratio of 14.50, OSE is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of OSE indicates a rather cheap valuation: OSE is cheaper than 87.32% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of OSE to the average of the S&P500 Index (20.44), we can say OSE is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.06 | ||
| Fwd PE | 14.5 |
4.2 Price Multiples
95.77% of the companies in the same industry are more expensive than OSE, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, OSE is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.78 | ||
| EV/EBITDA | 3.21 |
4.3 Compensation for Growth
A cheap valuation may be justified as OSE's earnings are expected to decrease with -57.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.7%
EPS Next 3Y-57.77%
5. Dividend
5.1 Amount
OSE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:OSE (5/9/2025, 7:00:00 PM)
6.005
+0.14 (+2.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.53%
Inst Owner ChangeN/A
Ins Owners24.72%
Ins Owner ChangeN/A
Market Cap134.21M
Analysts82.22
Price Target16.83 (180.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.48%
PT rev (3m)16.03%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-44.22%
EPS NY rev (3m)-46.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.18%
Revenue NY rev (3m)-18.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.06 | ||
| Fwd PE | 14.5 | ||
| P/S | 1.61 | ||
| P/FCF | 2.78 | ||
| P/OCF | 2.77 | ||
| P/B | 2.1 | ||
| P/tB | 6.78 | ||
| EV/EBITDA | 3.21 |
EPS(TTM)1.48
EY24.65%
EPS(NY)0.41
Fwd EY6.9%
FCF(TTM)2.16
FCFY36.03%
OCF(TTM)2.17
OCFY36.09%
SpS3.73
BVpS2.86
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.21% | ||
| ROE | 58.68% | ||
| ROCE | 42.16% | ||
| ROIC | 30.99% | ||
| ROICexc | 36.95% | ||
| ROICexgc | 74.79% | ||
| OM | 52.42% | ||
| PM (TTM) | 44.88% | ||
| GM | N/A | ||
| FCFM | 57.96% |
ROA(3y)-5.74%
ROA(5y)-10.16%
ROE(3y)-31.96%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 0.95 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 1.23% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.9% | ||
| Profit Quality | 129.16% | ||
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | 3.42 |
F-Score8
WACC7.45%
ROIC/WACC4.16
Cap/Depr(3y)5.25%
Cap/Depr(5y)12.46%
Cap/Sales(3y)4%
Cap/Sales(5y)3.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)225.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%372.26%
EPS Next Y-82.85%
EPS Next 2Y-63.7%
EPS Next 3Y-57.77%
EPS Next 5YN/A
Revenue 1Y (TTM)3646.52%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%9501.27%
Revenue Next Year-47.32%
Revenue Next 2Y-20.24%
Revenue Next 3Y-28.54%
Revenue Next 5YN/A
EBIT growth 1Y287.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-72.82%
EBIT Next 3Y-64.61%
EBIT Next 5YN/A
FCF growth 1Y341.85%
FCF growth 3YN/A
FCF growth 5Y40.61%
OCF growth 1Y345.08%
OCF growth 3YN/A
OCF growth 5Y39.6%